A new analysis suggests that taking a low dose of aspirin may modestly reduce the risk of developing colon cancer. But experts say aspirin's side effects of bleeding and stomach problems are too worrisome for most people to take the drug for that reason alone.
Sono-Tek Corporation has launched the 180kHz nozzle upgrade for its MediCoat DES 1000 and MediCoat II anti-restinosis stent coating systems. The 180 kHz ultrasonic nozzle creates a drop several microns smaller than that of the typically used 120 kHz nozzle.
American Type Culture Collection , a bioresource center, offers human umbilical vein endothelial cells (HUVEC) as part of its Primary Cell Solutions for cardiovascular research.
For the first time, researchers have discovered a disease mechanism that links hereditary amyotrophic lateral sclerosis to the more common "sporadic" form of ALS -- and points to a possible therapeutic target.
A common virus that can cause coughing and mild diarrhea appears to have a major redemptive quality: the ability to kill cancer. Harnessing that power, researchers are conducting a clinical trial to see if the virus can target and kill certain tumor types.
Cells require the a team of molecules to prevent them from destroying themselves. This self-destructive tendency can be a good thing, as when dangerous precancerous cells are permitted to kill themselves, but it can also go horribly wrong.
Scientists are reporting evidence that black rice — a little-known variety of the grain that is the staple food for one-third of the world population — may help soothe the inflammation involved in allergies, asthma, and other diseases.
New data presented at the 32nd Annual Meeting of The American Society for Bone and Mineral Research provided further information on the potential of odanacatib to increase bone density, cortical thickness and bone strength when treating osteoporosis.
Cytheris SA announced the initiation of Phase 2 clinical trial of the company’s investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs, raltegravir and maraviroc.
Gilead Sciences, Inc. announced its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009.
GlaxoSmithKline announcement to develop and market gene therapy treatments for rare genetic disorders signals a “next step” for the field of gene therapy, according to the American Society of Gene & Cell Therapy.
ImmuPharma plans to file a US IND in the next few months and to commence a Phase 2b program the first half of 2011 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer.
Teva Pharmaceutical Industries Ltd. announced new data from the PreCISe study demonstrating that earlier initiation of treatment with Copaxone in patients presenting with first signs of multiple sclerosis provided greater effects.
Metabolon, Inc., a leader in global metabolomics, biomarker discovery and biochemical analysis, announced that the United States Patent and Trademark Office has granted patent 7,807,138 entitled “Biomarkers of Metabolic Responses to Hepatic Drugs”.
Genentech announced the Food and Drug Administration has approved Herceptin with chemotherapy for HER2-positive metastatic cancer of the stomach or gastroesophageal junction, for patients who have not been treated for their metastatic disease.